MannKind to Showcase at the Jefferies Global Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2025
0mins
Should l Buy ?
Source: Globenewswire
Conference Announcement: MannKind Corporation's CEO Michael Castagna and CFO Chris Prentiss will present updates at the Jefferies London Healthcare Conference on November 19, 2025, at 6:30 am ET/11:30 am GMT.
Webcast Availability: A live audio webcast of the presentation will be accessible on MannKind's website, with recorded versions available for 90 days post-conference.
Company Overview: MannKind Corporation is a biopharmaceutical company focused on innovative solutions for chronic diseases, particularly in cardiometabolic and orphan lung diseases.
Therapeutic Focus: The company develops treatments for serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
